This inventor holds 1 USPTO granted patent. Top assignees: The University of Texas System, Other. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2013
Title: Gideon Strassmann: Innovator in Cell Transdifferentiation
Introduction
Gideon Strassmann is a notable inventor based in Naples, FL (US). He has made significant contributions to the field of cell biology, particularly in the area of transdifferentiation. His innovative methods have the potential to impact various medical applications.
Latest Patents
Strassmann holds a patent for "Methods for transdifferentiating cells." This invention provides methods for affecting and altering the differentiation state of a cell. Specifically, it offers techniques to transdifferentiate a cell into an endothelial cell or a hematopoietic cell. The process involves the use of a demethylating agent, such as 5-azacytidine, to influence the differentiation state. The invention demonstrates the transdifferentiation of various cell types, including normal fibroblasts, into distinct cell types. This is achieved through the selection of specific growth factors that, in conjunction with demethylating agents, direct the differentiation path. The invention presents a novel approach to generating useful cell types for numerous medical applications.
Career Highlights
Throughout his career, Gideon Strassmann has worked with prestigious institutions, including the University of Texas System. His work has contributed to advancements in cell differentiation and regenerative medicine.
Collaborations
Strassmann has collaborated with notable professionals in his field, including Zeev Estrov. Their joint efforts have furthered research and development in cell transdifferentiation techniques.
Conclusion
Gideon Strassmann's innovative work in cell transdifferentiation showcases his commitment to advancing medical science. His contributions have the potential to revolutionize treatments and therapies in regenerative medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile